Page 1

Exhibit 99.1 & Janux Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • • • JANX007 Phase 1b enrollment continues across taxane - naïve monotherapy and darolutamide combination cohorts JANX014 Phase 1 study continues enrolling patients with metastatic castration - resistant prostate cancer ( mCRPC ) • JANX011 Phase 1 healthy volunteer study progressing as planned JANX013 remains on track for clinical initiation in the second half of 2026 Strong balance sheet supports advancement of multiple clinical programs with $ 970.9 million in cash , cash equivalents and short - term investments at end of 2026 SAN DIEGO , August 6 , 2026 – Janux Therapeutics , Inc. ( Nasdaq : JANX ) ( Janux ) , a clinical - stage biopharmaceutical company developing a broad pipeline of novel immunotherapies , today reported financial results for the quarter ended June 30 , 2026 , and provided a business update . " During the second quarter we continued to execute across our clinical portfolio while preparing for multiple upcoming milestones , " said David Campbell , Ph.D. , President and Chief Executive Officer of Janux . " Enrollment continues across our prostate cancer programs , including JANX007 and JANX014 , and we remain on track to initiate clinical development of JANX013 later this year . We also continue to make progress with JANX011 in healthy volunteers as we advance our autoimmune disease pipeline . " BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS : Clinical & Pipeline Progress • • • JANX007 ( PSMA - TRACTr ) continues to enroll in its Phase 1b trial in metastatic castration - resistant prostate cancer ( mCRPC ) , with ongoing dose optimization and expansion in taxane - naïve patients . • An expansion cohort evaluating JANX007 in combination with darolutamide , an androgen receptor pathway inhibitor , is actively enrolling in taxane - naïve mCRPC . JANX014 ( PSMA - TRACTr ) , a double - masked tumor - activated T cell engager , continues enrollment in its Phase 1 clinical study designed to evaluate safety , pharmacokinetics and preliminary antitumor activity . JANX011 ( CD19 - ARM ) continues enrolling in its Phase 1 clinical trial in healthy volunteers . The Company continues to advance additional TRACTr , TRACIr and ARM programs for potential future development . Upcoming Milestones • • Initial clinical data from the Phase 1 healthy volunteer study of JANX011 expected to be announced in the second half of 2026 . Clinical initiation of JANX013 , a PSMA - targeted CD28 costimulatory TRACIr , expected in the second half of 2026 .